Business Wire

Rhizen Pharmaceuticals AG Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530) in Locally Advanced or Metastatic Breast Cancer Patients

Share

Rhizen Pharmaceuticals AG (Rhizen), a Switzerland-based privately held, clinical-stage oncology & inflammation-focussed biopharmaceutical company announced today that it has commenced dosing in a phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K δ/γ inhibitor with additional SIK3 activity) in patients with locally advanced or metastatic breast cancer. This multi-center, randomized phase II study is being conducted in eastern Europe and is designed to assess Tenalisib’s anti-tumor activity and safety across two dose levels.The study also includes translational assessments intended to delineate the effect of Tenalisib’s multivalent mechanism on relevant cytokines/chemokine levels and gene expression changes within the tumor microenvironment.

Rhizen indicated that Tenalisib, in addition to its selective dual PI3K δ/γ inhibitory activity, also has Salt-Inducible Kinase 3 (SIK3) activity via its principal metabolite, that could potentially contribute to its chemo-sensitization effect as observed in its preclinical studies, especially in breast cancer. Rhizen hopes to establish the single agent activity of Tenalisib in this current study after which it plans to expand the assessment across additional solid tumor indications and combinations both with chemotherapeutic agents and with immune-checkpoint inhibitors.

PI3K inhibition continues to remain a relevant therapeutic intervention across tumor types given the importance of its signalling in tumor development. We have demonstrated our ability to develop safe and differentiated isoform selective PI3K inhibitors that can withstand the rigors of development and be integrated into clinical practice” said Swaroop Vakkalanka, Founder & CEO of Rhizen Pharma. Swaroop also added that “This is a sentinel study that we expect will pave the way for Tenalisib’s potential to be expanded beyond haematological cancers into solid tumors, given its stellar safety profile, multivalent activity and consequent combinability.

About Tenalisib (RP6530):

Tenalisib (RP6530) is a highly selective, next-generation, orally active, dual PI3K δ/γ inhibitor with additional SIK3 activity, that is currently in phase II clinical development for haematological malignancies & solid tumors. Tenalisib has been granted US FDA Fast Track & Orphan-Drug Designations for treatment of r/r PTCL and CTCL and had recently published data from its phase II study evaluating Tenalisib both as monotherapy and in combination with Romidepsin in r/r PTCL & CTCL which showed robust responses of ~75% ORR in r/r PTCL and ~54% in r/r CTCL. The combination was well tolerated with no additional toxicities noted over & above those of the individual agents, confirming Tenalisib’s superior safety profile in its class. Overall, Tenalisib has been studied in over 165 patients across studies till now and has shown potentially better safety outcomes vis-à-vis other agents in the PI3K class.

About Rhizen Pharmaceuticals AG.:

Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology & inflammation therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways.

Rhizen has proven expertise in the PI3K modulator space with the discovery of our first PI3Kδ & CK1ε asset Umbralisib, that has been successfully developed & commercialized in MZL & FL by our licensing partner TG Therapeutics (TGTX) in USA. Beyond this, Rhizen has a deep oncology & inflammation pipeline spanning discovery to phase II clinical development stages.

Rhizen is headquartered in Basel, Switzerland. For additional information, please visit https://www.rhizen.com/

Forward-looking statements

This press release may contain certain forward-looking statements relating to the company and its business. Although the company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rhizen Pharmaceuticals AG - Contact:

Samyukta Bhagwati
Manager, Corporate Affairs & Communications
Rhizen Pharmaceuticals AG.
Telephone: +41 32 580 0113
Email: corpcomm@rhizen.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vodafone Connects Its Customers With Thales’ Eco-SIM Card21.10.2021 08:00:00 CEST | Press release

Thales to supply Vodafone Group with Eco-SIM; a product whose card body is made out of 100% recycled plastic from refrigerator interiors. Vodafone initially plans to deploy Eco-SIM in ten countries1 in Europe and Africa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020006111/en/ Credit Vodafone Over 4.5 billion SIM cards are produced every year2, representing 20,000 tons of plastic – the equivalent weight of two Eiffel towers. Developed in partnership with Veolia, the global leader in ecological transformation, the Thales Eco-SIM was launched in 2020 and is made from 100% recycled polystyrene recovered from discarded refrigerators. Offering a second life to the refrigerator interiors, Thales enabled an independent and exclusive green plastic supply flow to Vodafone. Thales’ carbon offsetting program also ensures its innovative ‘green SIM’ is certified as carbon neutral3. As a result, the new contract will support Vodafo

Gaïa Rating - New Award for ESI Group's ESG Commitment21.10.2021 08:00:00 CEST | Press release

Regulatory News: Gaïa Research, a service of EthiFinance and a major player in the field of ESG rating (environment, social and governance) of French mid-sized listed companies, has awarded ESI Group (Paris:ESI), a global player in virtual prototyping, committed to a cleaner, safer, and more productive industry, the first Gaïa 2021 prize in the category of mid-cap companies with annual revenues under €150 million. This award received during the ceremony held on October 19th, 2021 in Paris, illustrates the efforts made by the Group to continuously improve its CSR commitments (social, societal, and environmental). 2021 was shaped by several significant actions for ESI Group, both within its governance, its environmental commitments, some in collaboration with Reforest'Action, and above all, with initiatives dedicated to its employees. Particularly shaken by the Covid-19 health crisis, the work-life balance was a field of action for ESI Group, which employs 1,200 people in about 20 countr

Boyd Corporation Acquires Siltec, Continues to Expand Global Material Science Portfolio21.10.2021 08:00:00 CEST | Press release

Boyd Corporation, a world-leading innovator of technologies in engineered materials and thermal management, today announced the acquisition of Siltec, a Weiler, Germany-based specialist in silicone compounding for custom products in the highly-regulated medical industry. The acquisition deepens and diversifies Boyd’s material science portfolio and further expands its European footprint. “Siltec’s dedicated team of scientists and technologists enhance Boyd competencies in silicone material science and the medical industry. We’ll leverage this expertise to accelerate innovation across Boyd’s material portfolio and adjacent high growth markets like industrial technology, eMobility and cloud data center where customers need high temperature resistant and durable solutions,” stated Boyd CEO Doug Britt. Boyd continues to invest in value-driven innovation and technology to create marketable differentiation for its customers. The addition of silicone compounding expertise further bolsters Boyd

ADVA manages supply constraints and grows revenues and profitability in Q3 202121.10.2021 07:00:00 CEST | Press release

ADVA (ISIN: DE0005103006, FSE: ADV), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported its financial results for Q3 2021 ended on September 30, 2021. The results have been prepared in accordance with International Financial Reporting Standards (IFRS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005879/en/ Brian Protiva, CEO, ADVA (Photo: Business Wire) Q3 2021 financial summary1 (in thousands of EUR) Q3 Q3 Change Q2 Change 2021 2020 2021 Revenues 151,777 146,676 3.5% 149,354 1.6% Pro forma gross profit 52,153 51,930 0.4% 57,274 -8.9% in % of revenues 34.4% 35.4% -1.0pp 38.3% -3.9pp Pro forma operating income 13,012 11,053 17.7% 14,415 -9.7% in % of revenues 8.6% 7.5% 1.1pp 9.7% -1.1pp Operating income (loss)2 9,496 9,768 -2.8% 13,036 -27.2% Net income 18,478 6,671 177.0% 12,001 54.0% (in thousands of EUR) Sep. 30 2021 Sep. 30 2020 Change Jun. 30 2021 Change Cash

Tigo Energy to Showcase Solutions for Roof Space Usage, Monitoring, and Safety at Key Energy21.10.2021 07:00:00 CEST | Press release

Tigo Energy, Inc., the solar industry’s worldwide leader in Flex Module Level Power Electronics (MLPE), today announced the Company’s presence as an exhibitor at the upcoming Key Energy in Rimini, Italy. Tigo representatives will showcase all of its TS4 Flex MLPE devices, including the recently released TS4-A-O, compatible with all PV modules up to 700Wp, and the Tigo Energy Intelligence (EI) software platform. Together, these products are the most cost-effective and advanced solution for optimization and module-level monitoring for small to large-scale solar projects. “Key Energy is a big event for us and we are excited to once again meet with our customers in person, especially right on the heels of releasing the restyled layout for residential and storage applications in our new EI software platform,” said Mirko Bindi, Vice President EMEA Sales and MD Europe at Tigo Energy. “Moreover, our new TS4-A-O, with a 700Wp max power rating, covers all the modules currently available in the m

ABB: Q3 2021 Results21.10.2021 06:53:00 CEST | Press release

ABB (SWX:ABBN): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020006194/en/ KEY FIGURES CHANGE CHANGE ($ millions, unless otherwise indicated) Q3 2021 Q3 2020 US$ Comparable1 9M 2021 9M 2020 US$ Comparable1 Orders 7,866 6,109 29% 26% 23,611 19,509 21% 16% Revenues 7,028 6,582 7% 4% 21,378 18,952 13% 8% Gross Profit 2,294 1,834 25% 7,070 5,731 23% as % of revenues 32.6% 27.9% +4.7 pts 33.1% 30.2% +2.9 pts Income from operations 852 71 n.a. 2,743 1,015 170% Operational EBITA1 1,062 787 35% 32% 3 3,134 2,074 51% 43% 3 as % of operational revenues1 15.1% 12.0% +3.1 pts 14.6% 10.9% +3.7 pts Income (loss) from continuing operations, net of tax 687 (503) n.a. 2,027 218 830% Net income attributable to ABB 652 4,530 -86% 1,906 5,225 -64% Basic earnings per share ($) 0.33 2.14 -85%2 0.95 2.45 -61%2 Cash flow from operating activities4 1,104 408 171% 2,310 511 352% Cash flow from operating activities in continuing operations 1,119

China is Flying High Again: Cirium Survey Shows Remarkable Consumer Confidence for a Travel Restart21.10.2021 04:00:00 CEST | Press release

Chinese travelers are leading the airline travel recovery, with 96% intending to travel, according to a new survey by Cirium, the aviation analytics company. 81% of respondents say they plan to fly at least once within the next 12 months and 50% plan to fly by this autumn. Of those planning to travel, 73% stated it was for leisure with only 24% planning business travel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005941/en/ Cirium's new Traveler Intelligence Report reveals China is flying high again. (Graphic: Business Wire) The pent-up demand is also reflected in China’s passenger traffic, which is showing signs of a strong recovery. As of September 2021, China traffic was at 87% of 2019 levels — way ahead the rest of Asia (42%). The survey revealed that two thirds (66%) of Chinese travelers have taken a domestic flight since the start of the pandemic. Cirium schedules data reveal domestic travel in Q4 is primed to